Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 1999

View Archived Issues

Nycomed Amersham: year-end 1998 highlights

Shire: year-end 1998 highlights

Bioniche enters supply agreement with Sanova for Suplasyn

Antisoma's Theragyn granted orphan drug status in the U.S.

Novel furansulfonic acid compounds for neurodegenerative, autoimmune and inflammatory disorders

Roche presents new metabotropic glutamate receptor ligands in the patent literature

Potassium channel modulators for neurological disorders developed at Bristol-Myers Squibb

Noncardiotoxic anthracyclines disclosed by Gem

New anticoagulants/antithrombotics revealed by Zeneca

Potent, selective human beta3-AR agonist characterized by Merck & Co.

Highly potent and selective Y1 receptor antagonists designed at Lilly

Potent, orally active glucagon antagonist developed at Merck & Co.

Ibex implements major changes in new phase III study of Neutralase

Cytel halts clinical trials of Cylexin; company to focus on Epimmune's vaccine programs

Prosorba Column now available in U.S. for treatment of rheumatoid arthritis

Celgene and NCI collaborate on thalidomide cancer trial

FDA approves DepoCyt for treatment of lymphomatous meningitis

Targeted Genetics reports findings of gene therapy trial in cystic fibrosis

Terms of NeuroCell transfer proposal detailed by Genzyme Tissue Repair

Tasosartan provides effective control of essential hypertension in 10-week study

Zeneca files sNDA for change in dosing for Zestril

CAT and Wyeth-Ayerst initiate broad-based target validation and product development collaboration

Regeneron and P&G initiate diabetes-associated obesity trial of Axokine

FDA approval granted for BioTime's blood plasma volume expander

M-Vax cancer vaccine granted orphan drug designation

All rights to INFeD return to Schein

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.